Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levornidazole and Sodium Chloride Injection in Pelvic Anaerobic Infection: PK and Safety
CTR20260362Phase 4Active
- Sponsor
- Shijiazhuang No. 4 Pharmaceutical
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of levornidazole in Pelviabdominal infection, amebiasis, surgical site infection (SSI), anaerobic infection, sponsored by Shijiazhuang No. 4 Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
levornidazole
03
Conditions
Pelviabdominal infectionamebiasissurgical site infection (SSI)anaerobic infection
Beyond the preview
Go deeper on CTR20260362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260362.